UCP (Ultrasound Cyclo Plasty) in the Treatment of Chinese Patients With Primary Open-angle Glaucoma

Last updated: March 23, 2020
Sponsor: Zhongshan Ophthalmic Center, Sun Yat-sen University
Overall Status: Active - Recruiting

Phase

N/A

Condition

Glaucoma

Treatment

N/A

Clinical Study ID

NCT04321122
2018QXPJ005
  • Ages 18-90
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

Traditional ciliary body photocoagulation treatment uses the photocoagulation of long-wavelength laser to destroy the ciliary body tissue that can produce aqueous humor. Therefore, it is a kind of palliative treatment which has proved efficacy but causes great pain to patients. The "ultrasonic glaucoma treatment instrument" produced by French EYE TECH CARE company is referred to as EyeOP1. It uses high-intensity focused ultrasound technique to make target part of the ciliary coagulative necrosis, reduce the production of aqueous humor and thereby lower the intraocular pressure. EyeOP1 is ergonomic and suitable for the human eye, making the treatment process more accurate, simple and fast.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • The target eye was diagnosed as primary open-angle glaucoma; diagnostic criteria:IOP(intraocular pressure)≥ 21, open angle, typical glaucoma visual field and opticdisc damage;

  • Patients treated with glaucoma medications cannot control intraocular pressureeffectively;

  • Patients with 21mmHg ≤ IOP ≤ 30mmHg;

  • VA(visual acuity)≥HM(hand motions);

  • Patients that have failed conventional glaucoma surgery (trabeculectomy) or are notsuitable for surgery;

  • Patients who have not received intraocular surgery or laser treatment 90 days beforereceiving HIFU;

  • Aged from 18 to 90 years old;

  • Sign informed consent and be willing to provide visit data;

Exclusion

Exclusion Criteria:

  • Either eye have any infections two weeks before the surgery;

  • The target eye has history of ciliary surgery, intraocular or retrobulbar tumor;

  • The target eye is neovascular glaucoma;

  • The target eye is aphakic eye;

  • Anterior anatomical abnormalities cause scleral expansion or ciliary body ectopic;

  • Non-glaucoma intraocular diseases that affect intraocular pressure;

  • Within 30 days, the patient participated in or was simultaneously included in otherclinical trials;

  • Patients during pregnancy or lactation;

  • Any systemic disease that may affect patient follow-up.

Study Design

Total Participants: 60
Study Start date:
August 12, 2018
Estimated Completion Date:
June 12, 2020

Study Description

  1. Efficacy: 1. Main objective: (1)Assess the decrease in postoperative intraocular pressure from baseline and evaluate the final results (the percentage of patients whose conditions have significant improved and the variation of the percentage of median intraocular pressure. (2)Assess the amount of medication after surgery.

  2. Secondary goals:(1) Compare median intraocular pressure with baseline at each postoperative follow-up and access the variation of median intraocular pressure from baseline at each postoperative follow-up. (2) Count the number of intraocular pressure lowering drugs at each postoperative follow-up.

b.Safety: Investigate the incidence of all device-related(or procedure-related) adverse events during the study (intraoperative and postoperative follow-up).

Connect with a study center

  • Zhognshan Ophthalmic Center, Sun Yat-sen University

    Guangzhou, Guangdong 510060
    China

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.